Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New imaging methods could transform PMR diagnosis

NCT ID NCT04519580

Diagnosis Sponsor: Kresten Krarup Keller Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study explores whether ultrasound and PET/CT scans can more accurately diagnose and monitor polymyalgia rheumatica (PMR), a condition causing muscle pain and inflammation. Researchers will follow 98 adults over 50 suspected of having PMR, using imaging at key points during treatment. The goal is to reduce reliance on exclusion diagnosis and improve disease tracking.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

98 people

The number who actually took part.

Started

Sep 2020

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will include patients suspected for PMR.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients suspected of PMR. * Age above 50 * Pain of the proximal muscles. Exclusion Criteria: * Peroral, intraarticular, intramuscular and dermal application of glucocorticoids within the last 3 month. * Previous prednisolone treatment for GCA/PMR * Unable to give consent. * Symptoms of GCA (headache, jaw claudication, vision disturbances). * Active malignant cancers within the last 5 years (except basal cell carcinoma). * Other inflammatory rheumatic diseases (eg. rheumatoid arthritis, polymyositis, spondyloarthritis, psoriatic arthritits, gout). * Uncontrolled diseases (eg severe active astma, cardiac disease with NYHA class IV) * Treatment with peroral oestrogens, aminogluthethimid, trilostan, ketoconazole, fluconazol, etomidate, phenobarbital, phenytoin, rifampicin, metyrapon, mitotane. * Known primary or secondary adrenal insufficiency.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adrenal insufficiency are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

adrenocortical insufficiency Giant Cell Arteritis polymyalgia rheumatica temporal arteritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adrenal insufficiency Giant cell arteritis Polymyalgia rheumatica

Contacts and locations

Locations

  • Department of Rheumatology, Aarhus University Hospital

    Aarhus, 8200, Denmark

  • Department of Rheumatology, Horsens Regional Hospital

    Horsens, 8700, Denmark

  • Diagnostic Centre, Silkeborg Regional Hospital

    Silkeborg, 8600, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.